Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519525 · ClinicalTrials.gov registry record · Phase 1
A Study of [14C]-LY4064809 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT07519525: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT07519525 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07519525, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.
Interventions
- DRUG LY4064809
- DRUG [14C]-LY4064809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2026-05-26 |
| Phase | Phase 1 |
What the finished NCT07519525 record still lists
NCT07519525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which LY4064809 is the first listed.
NCT07519525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07519525 about?
NCT07519525 is a clinical study titled "A Study of [14C]-LY4064809 in Healthy Participants". The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including ...
What is the current status of trial NCT07519525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2026-03-27. Estimated completion is 2026-05-26.
What interventions are being tested in trial NCT07519525?
The interventions under investigation include: LY4064809 (DRUG), [14C]-LY4064809 (DRUG).
Who is sponsoring clinical trial NCT07519525?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07519525's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI